Goldman Sachs Initiates Coverage of Exact Sciences with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb) – Goldman Sachs today initiated coverage of Exact Sciences with a Buy rating, calling the company's colorectal cancer screening test "the best new product cycle in our coverage."

In a report, analyst Isaac Ro gave Exact Sciences' shares a six-month price target of $19 and noted three catalysts to the molecular diagnostic firm's stock — US Food and Drug Administration approval and Centers for Medicare and Medicaid Services reimbursement; a concentrated sales channel that is undervalued; and an undemanding valuation on the company's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.